drugset / Trial / NCT01440309

Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis

NCT01440309

RandomizedParallel-groupOpen-labelTreatment

Summary

The study is designed to evaluate the safety and efficacy of intravenous administration of bone marrow derived mesenchymal stem cells for patients with refractory primary biliary cirrhosis (PBC).

Timeline

Start
2011-11
Primary completion
2013-11
Completion
2013-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesenchymal stem cell Cell therapy 5e+06 cells/kg Intravenous
Subject Mesenchymal stem cell Cell therapy 5e+07 cells/kg Intravenous
Comparator Ursodeoxycholic Acid Small molecule 13 mg/kg
Comparator Ursodeoxycholic Acid Small molecule 15 mg/kg